Clinical Trial

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 13, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CART cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-06.
Trial Details
NCT Number NCT06126406
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: First Affiliated Hospital of Wannan Medical College
Conditions Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas Cancer
Enrollment 60 participants
Start Date 2023-11-06
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-11-13